R Squared’s Axsome Therapeutics AXSM Stock Holding History

R Squared’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-760	Closed	-$64.3K	–	414
2024 Q4	$64.3K	Buy	+760	New	+$69.9K	0.06%	406

Other funds holding AXSM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

R Squared's AXSM Position: Q1 2025 in Review

R Squared sold out of Axsome Therapeutics (AXSM) in Q1 2025, closing a stake of 760 shares — an estimated $64.3K sold.

R Squared first reported a position in AXSM in Q4 2024 and held it in 1 quarter. The position peaked at $64.3K in Q4 2024. 353 funds tracked by Wall St. Rank hold AXSM as of Q1 2025.

R Squared reported no remaining Axsome Therapeutics position as of Q1 2025 after selling out during the quarter.
R Squared sold 760 Axsome Therapeutics shares in Q1 2025, an estimated $64.3K.
R Squared first reported a position in Axsome Therapeutics in Q4 2024 and held it in 1 quarter.
R Squared's Axsome Therapeutics position peaked at $64.3K in Q4 2024.
353 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.